中国卵巢癌疾病负担现状及趋势分析

Current Status and Trend Analysis of Ovarian Cancer Disease Burden in China

目的:分析1990—2019年中国卵巢癌疾病负担现状及变化趋势,为卵巢癌的防控提供科学依据。方法:用2019年全球疾病负担(Global Burden of Disease 2019,GBD 2019)数据,收集1990—2019年中国、美国、俄罗斯、日本、印度和全球女性卵巢癌的标化患病率、标化发病率、标化死亡率和标化伤残调整生命年(disability adjusted life year,DALY)率,对比分析中国女性卵巢癌情况。结果:1990—2019年中国卵巢癌4项指标均呈显著增长趋势,标化患病率从1990年的10.11/10万上升至2019年的20.44/10万,标化发病率从2.56/10万上升至4.54/10万,标化死亡率1.76/10万上升至2.77/10万,标化DALY率从55.57/10万上升至80.52/10万。相较于全球总体情况及纳入分析的其他4个国家,2019年中国卵巢癌4项指标水平均较低,但近30年间中国的3项指标(标化患病率、标化发病率、标化死亡率)增幅均最大,分别为202.18%、177.34%和157.39%。结论:1990—2019年中国卵巢癌疾病负担呈大幅增长趋势,应采取相关措施予以重视预防与控制。

Objective:To analyze current status and trend of ovarian cancer burden in China from 1990 to 2019,in order to provide scientific basis for prevention and control of ovarian cancer.Methods:Global burden of disease(GBD)2019 data were used to collect the standardized rate of prevalence(SPR),incidence(SIR),mortality(SMR),and disability adjusted life year(DALY)of ovarian cancer in China.The US,Russia,Japan,India,and Global from 1990 to 2019,so as to comparative analysis the ovarian cancer situation in Chinese women.Results:From 1990 to 2019,all four indicators of ovarian cancer in China showed a significant rising trend,with the SPR increasing from 10.11/100000 in 1990 to 20.44/100000 in 2019,the SIR increasing from 2.56/100000 to 4.54/100000 and the SMR increasing from 1.76/100000 to 2.77/100000 and the standardized DALY rate increased from 55.57/100000 to 80.52/100000.Compared with the overall global situation and the four countries included in the analysis,all four indicators in China were all at the low level in 2019,but China had the largest growth in three indicators(SPR,SIR,SMR)over the past 30 years,202.18%,177.34%,157.39%respectively.Conclusions:From 1990 to 2019,the disease burden of ovarian cancer in China has shown a substantial increase,it turns out that relevant measures should be taken to pay attention to prevention and control.